GlassScriptPhysician profile
Eduardo A Sanchez
NPI 1457403800
$3,262.23
in general payments reported to CMS, 2019-2025
14 companies · $202 in 2025
The $202 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $629 · 2020: $299 · 2021: $716 · 2022: $655 · 2023: $587 · 2024: $174 · 2025: $202.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $963.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $962.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $928.37 | 2021-2025 | Vraylar |
| Allergan, INC. | $354.06 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $331.14 | 2019-2025 | Trintellix |
| Teva Pharmaceuticals USA, INC. | $311.88 | 2019-2023 | Austedo Xr, Austedo |
| Sunovion Pharmaceuticals INC. | $304.55 | 2019-2022 | |
| Lundbeck LLC | $258.28 | 2019-2023 | Rexulti |
| Idorsia Pharmaceuticals US INC | $228.51 | 2022-2024 | Quviviq |
| Avanir Pharmaceuticals, INC. | $140.35 | 2019-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $136.38 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $127.55 | 2023-2025 | Nuedexta, Rexulti |
| Janssen Pharmaceuticals, INC | $47.95 | 2019-2020 | |
| Scilex Pharmaceuticals INC. | $47.31 | 2019 | |
| Axsome Therapeutics, INC. | $25.41 | 2022 | |
| Alkermes, INC. | $20.49 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eduardo Sanchez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.